Implantica

Q1 Interim Report

JANUARY ▸ MARCH 2026

Financial Summary

Figures within parentheses refer to the preceding year.

First Quarter

- Net sales increased 15% to TEUR 857 (745).
- Adjusted gross margin amounted to 93% (97%).
- Operating loss (EBIT) improved to TEUR 3,858 (4,173).
- Loss after tax increased to TEUR 4,280 (2,764).
- Basic and diluted loss per Class A share amounted to EUR 0.06 (0.04).
- Cash at the end of the period amounted to MEUR 45.5.

Significant Events

IN THE FIRST QUARTER OF 2026

- Secured over EUR 1.2 million in new multi-year public tender approvals in Italy, further strengthening RefluxStop®'s commercial adoption and reimbursement position within the Italian national healthcare system
- Expanded the RefluxStop® Centers of Excellence network in Germany with the addition of Klinikum St. Georg in Leipzig and St. Vincenz Hospital Menden, both InEK reporting hospitals supporting Implantica's reimbursement strategy through the InEK DRG adjustment process
- Published additional health economics analysis in Italy demonstrating that RefluxStop® is highly cost-effective compared to traditional GERD treatments, PPI medication, Fundoplication and MSA procedures, further supporting its long-term reimbursement and market access potential

AFTER THE END OF THE PERIOD

- Submitted final FDA response including additional test reports requested by the FDA for the RefluxStop® PMA application
- Continued accelerating preparations for a targeted U.S. commercial launch of RefluxStop®, pending FDA approval
- Landmark real-world RefluxStop® study published in Nature's Scientific Reports, demonstrating excellent long-term safety and reproducibility across 602 GERD patients from 22 centers in six European countries with follow-up up to 6.75 years

Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop®

CEO Comments

The first quarter of 2026 marked a pivotal period for Implantica. We accelerated clinical validation, commercial traction, reimbursement progress, and market expansion of the RefluxStop® procedure as well as advancing the FDA PMA process. These key milestones further strengthened our strategic position. Our priority is the U.S. launch, pending FDA approval and to establish RefluxStop® as the standard of care, worldwide.

DR. PETER FORSELL
CEO, IMPLANTICA

Our years of focused market development work in Europe – building product adoption among top-tier surgeons and centers while generating high-quality long-term clinical data necessary for reimbursement and market access – continued to gain meaningful traction during the quarter. This was achieved through landmark clinical publications, growing commercial adoption, expanded scientific engagement, and supporting important progress toward U.S. market entry.

US Launch – Pending FDA approval

As recently announced, we submitted our final response to the FDA this week (including the additional tests requested by FDA) and now look forward to the completion of the PMA review process with the targeted commercial launch of RefluxStop® in the United States, pending FDA approval. This represents a major milestone for Implantica and reflects the substantial clinical, scientific, regulatory, and operational work completed over many years.

In parallel, we continue preparations for a targeted and strategically focused U.S. launch, including engagement with key opinion leaders. The increasing visibility and interest surrounding RefluxStop® among U.S. surgeons and gastroenterologists further strengthens our confidence in the long-term potential of the procedure in the U.S. market.

Landmark Publication of the Largest RefluxStop® Real-World Study

Our many years of collaboration with leading European surgical centers resulted in a landmark publication of the largest real-world RefluxStop® dataset to date. The study, titled "*Safety outcomes in 602 GERD patients treated by RefluxStop: a multi-center real-world study from 22 centers across six European countries*," with follow-up extending **up to 6.75 years**, was published in *Scientific Reports*, part of the prestigious Nature portfolio of journals.
The publication further reconfirmed the excellent long-term safety profile and reproducibility of the RefluxStop® procedure across a broad real-world patient population:

- 98% of patients experienced no serious safety issues requiring reoperation and were all resolved
- Exceptionally low reoperation rates were observed, with recurrence rates of repaired hiatal hernia (1.3%) tenfold lower than those historically reported for standard of care anti-reflux procedures
- Other serious adverse events were rare and no event occurred in >1 out of 602 patients. Furthermore, these were primarily associated with the learning curve seen with the introduction of a new surgical procedure

These findings continue to strengthen confidence in RefluxStop® among surgeons, hospitals, and healthcare systems. Crucially, independent real-world evidence demonstrating safety and reproducibility across diverse patient populations by a variety of surgeons is becoming increasingly important for reimbursement and market access decisions globally.

Expanding Centers of Excellence to Support German Reimbursement Strategy

During the quarter, we continued to expand our strategic network of RefluxStop® Centers of Excellence in Germany and other key markets, further growing our European footprint. We added Klinikum St. Georg in Leipzig, as well as St. Vincenz Hospital Menden in Germany. Importantly, both centers are InEK cost-reporting hospitals. In Germany we have already achieved our own code for the RefluxStop® procedure, however, the German healthcare body InEK needs to provide a reimbursement amount connected to the InEK DRG system. This is based on real costs reported from several hundred RefluxStop® procedures performed by InEK cost reporting hospitals.

Strong Scientific Engagement at Major U.S. Congresses Supporting Future U.S. Adoption of RefluxStop®

Scientific and medical engagement remained strong during the quarter, with RefluxStop® featured prominently at several major international congresses, including some of the most important foregut-focused meetings in the US:

At Digestive Disease Week (DDW) 2026 in Chicago, the world's largest international meeting dedicated to digestive health with over 13,000 participants, new long-term RefluxStop® data

generated strong interest among surgeons, gastroenterologists, and other experts from around the world.
Particularly notable was the presentation by Dr. med. Borbély from Inselspital, Bern, the largest university hospital in Switzerland. The prospective data presented highlighted excellent long-term safety and clinical outcomes in complex severe GERD sufferers, conditions that have historically had limited or poor treatment options. The 82 RefluxStop® patients were followed for up to 7.25 years, with 50% of patients now reaching four years follow up. The cohort included severe sufferers with:

- Nearly 25% had Barrett's esophagus, a precancerous condition
- 57% with poor food transportation where the esophagus to a high degree has been damaged by acid
- 6% suffered from aperistalsis, a condition in which the esophagus completely lacks normal contraction waves
- 55% had large hiatal hernia greater than 3 cm in size
- 4% lung transplant patients, including one prior to, were successfully treated using RefluxStop®, avoiding reflux damaging their transplanted lungs

These findings are highly encouraging, as they suggest that RefluxStop® may address a substantially broader patient population.

At SAGES 2026 in Tampa, Florida, the world's preeminent society for gastrointestinal and endoscopic surgeons, RefluxStop® was showcased to leading U.S. surgeons and gastroenterologists through multiple presentations highlighting the device's unique non-encircling mechanism of action and excellent clinical outcomes. Several leading European surgeons presented compelling clinical data and surgical experience including robot-assisted RefluxStop® procedures, which attracted strong interest among surgeons evaluating integration with advanced robotic surgical platforms.

In addition, RefluxStop® was featured at two other important U.S. foregut-focused meetings during the quarter, the Medical and Surgical Aspects of Esophageal & Foregut Disorders: Pathophysiology and Treatment – 2026 Course, in Hawaii, and 2026 Esophageal Symposium in Phoenix, Arizona.

Gaining Commercial Traction with Strong Economic Value Creation

In Italy, we achieved additional important commercial and reimbursement progress through the approval of two new multi-year public tenders at Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" in Palermo and Ospedale di Brunico (Azienda Sanitaria dell'Alto Adige) in South Tyrol. Together, these tenders secure more than EUR 1.2 million in public healthcare funding and further validate RefluxStop®'s growing acceptance within the Italian national healthcare system.

Further supporting the economic value proposition of RefluxStop®, a health economics analysis focused on the Italian healthcare system was published. Consistent with previously published articles on health economics analysis of reflux disease across the UK and Europe, this study demonstrated that RefluxStop is highly cost-effective compared to traditional standards of care, including PPI-based medical management, laparoscopic Nissen fundoplication, and magnetic sphincter augmentation (MSA) procedures, offering a large opportunity for reduced healthcare costs and resources optimization for the healthcare society in Italy, as well as other countries, for GERD management.

Looking Ahead: Advancing Toward Long-Term Growth

Overall, we are encouraged by the continued momentum across our business. The expanding body of long-term clinical evidence, increasing surgeon adoption, ongoing reimbursement progress, and advancement toward U.S. market entry continue to strengthen the foundation for sustainable long-term growth. The U.S. launch, pending FDA approval, provides an exciting future for Implantica.

While RefluxStop® remains our clear strategic priority, we continue to advance development activities across our broader implantable eHealth and wireless energizing platform technologies, which we believe hold substantial long-term potential to transform patient care across multiple applications.

Together, these efforts position Implantica not only to establish RefluxStop® as a potential new standard of care in the surgical treatment of GERD, with a treatment field of 1 billion sufferers (and approximately 78 million Americans), but also to build a broader innovation platform capable of transforming patient care across multiple chronic disease areas over time. Our e-health platform has substantial IP coverage, with >25 000 pages of patent filings, illustrating the enormous work that has been performed to protect a leading position in the future eHealth segment for smart medical implants. This is a very exciting journey starting to take off!

We thank our shareholders, employees, patients, and surgeons for their continued trust and support.

Yours sincerely,
Dr. med. Peter Forsell, *Surgeon and Inventor*
CEO and Founder, Implantica

IMPLANTICA IN BRIEF

Implantica is a MedTech group committed to providing effective care for serious health conditions and improving patient quality of life by bringing advanced technology into the body. Simultaneously, Implantica aims to reduce overall costs and improve efficiency in the healthcare system. The therapies Implantica develops are based on implants, which are inserted into the patient's body to replace bodily functions and/or treat diseases.

Implantica's most progressed product, RefluxStop®, represents a strong potential for a paradigm shift in the treatment of GERD, based on excellent clinical evidence. Acid reflux has a significant impact on patient quality of life and can induce serious complications, including increased risk for esophageal cancer.

GERD patients rely today, to a large extent, on PPIs – a drug therapy which calms the symptoms of GERD. Ultimately, with PPI treatment, the side effects are severe, involving a risk of early death (as published by Yan Xie et al. on >150,000 U.S. veterans taking PPI for 10 years[1]). Reflux of stomach fluid is not prevented by PPIs and the risk for developing esophageal cancer remains. According to a study by Brusselaers et al. from Karolinska Institute[2], 38% of all patients dying from esophageal cancer were PPI users.

Alternative surgical procedures available today are often plagued with complications, including affecting the food passageway and causing swallowing difficulties.

In addition to RefluxStop®, Implantica has developed two platform technologies: an eHealth platform and a wireless energizing platform as well as a broad, patent-protected product pipeline, two-thirds of which are based on the company's two platform technologies.

Bringing advanced technology and smart medical implants into the body requires enough power to activate a device inside the body long-term, which is the reason why a wireless energising platform has been developed. The eHealth platform is necessary for communicating with and reprogramming implants and adjusting treatment remotely.

These platform technologies are covered by a multitude of patents and patent applications.

References:

(1) Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.

(2) Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172-7.

Top ten shareholders as of 31 March 2026

Name	Capital (%)
Peter Forsell	46.6%
Handelsbanken Fonder	9.1%
EFG Bank	7.0%
UBS	3.6%
Avanza Pension	3.0%
UBP	2.8%
SEB Life	2.6%
SIX SIS AG	1.6%
Nordea Liv	1.4%
Stephan Siegenthaler	1.3%

Financial performance in brief

Figures in parentheses within the following section refer to the corresponding period in the preceding year.

Net sales

During the first quarter, revenue amounted to EUR 857 thousand (745), an increase of EUR 112 thousand, or 15%, compared to the corresponding period last year. Implantica currently solely markets its lead product, RefluxStop™, exclusively through selected Key Opinion Leaders in Europe.

Cost of sales and gross margin

Cost of sales during the first quarter amounted to EUR 364 thousand (330). Cost of sales comprises two categories of expenses. The first consists of indirect costs related to the straight-line amortisation of capitalised development costs associated with RefluxStop™. The second, Other cost of sales, includes direct costs for the procurement of goods and services from the Group's outsourcing partners.

In the first quarter, adjusted gross margin[1], defined as gross margin excluding amortisation, amounted to 93% (97%).

Operating result (EBIT)

In the first quarter, operating loss (EBIT) amounted to EUR 3,858 thousand (4,173), representing an improvement of EUR 315 thousand, or 8%, compared to the corresponding period last year.

Research and development costs amounted to EUR 1,695 thousand (1,576), corresponding to an increase of EUR 119 thousand, or 8%. The year-on-year increase in research and development costs was primarily driven by higher costs related to the post-market clinical studies.

General and administrative costs amounted to EUR 2,656 thousand (3,012), representing a decrease of EUR 356 thousand, or 12%, compared to the corresponding period last year.

Financial income and expenses

Financial income amounted to EUR 213 thousand (1,445) during the first quarter, mainly reflecting foreign exchange gains and interest income. Financial expenses amounted to EUR 632 thousand (32) during the quarter, driven by foreign exchange losses.

Income taxes

The Group reported a tax expense of EUR 3 thousand (4) in the first quarter. The tax expense for the quarter relates to current tax expense only.

Net earnings

The Group reported a net loss of EUR 4,280 thousand (2,764) for the first quarter, an increase of EUR 1,516 thousand compared with the corresponding period last year. The widening of the loss was primarily driven by the weaker financial net relative to the same period in the prior year.

Equity and liabilities

As of 31 March 2026, the Group's equity amounted to EUR 79.1 million (96.6), and the equity ratio stood at 96%, compared to 97% as of 31 March 2025.

As of 31 March 2026, the Group had no interest-bearing debt.

Cash flow and liquidity

During the first quarter, net cash outflow from operating activities amounted to EUR 3,660 thousand (4,525).

As of 31 March 2026, Implantica held cash of EUR 45.5 million.

Auditor's review

This report has not been reviewed by the company's auditors.

[1] Adjusted gross profit as a percentage of Net sales. Where Adjusted gross profit is defined as Net sales minus cost of sales, plus amortization of development costs.

Consolidated interim financial statements

Condensed consolidated statement of profit or loss

	Jan to Mar		Jan to Dec
in thousands of EUR	2026	2025	2025
Revenue	857	745	2,073
Cost of sales			
Amortisation of capitalized development costs	(307)	(307)	(1,227)
Other cost of sales	(57)	(23)	(136)
Total cost of sales	(364)	(330)	(1,363)
Gross profit	493	415	710
Impairment of development costs	-	-	(1,259)
Research and development costs (Note 4)	(1,695)	(1,576)	(7,354)
General and administrative costs	(2,656)	(3,012)	(12,620)
Operating loss	(3,858)	(4,173)	(20,523)
Financial income	213	1,445	937
Financial expenses	(632)	(32)	(197)
Loss before income taxes	(4,277)	(2,760)	(19,783)
Income taxes	(3)	(4)	(32)
Loss for the period	(4,280)	(2,764)	(19,815)
Attributable to			
Owners of Implantica AG	(4,263)	(2,709)	(19,626)
Non-controlling interests	(17)	(55)	(189)
Loss for the period	(4,280)	(2,764)	(19,815)
Earnings per share (Note 5)			
Basic and diluted loss per share Class A (in EUR)	(0.06)	(0.04)	(0.28)
Basic and diluted loss per share Class B (in EUR)	(0.00)	(0.00)	(0.00)

Condensed consolidated statement of profit or loss and other comprehensive income

in thousands of EUR	Jan to Mar 2026	Jan to Mar 2025	Jan to Dec 2025
Loss for the period	(4,280)	(2,764)	(19,815)
Other comprehensive income			
Remeasurement of net defined benefit liability	(22)	(65)	110
Total items that will not be reclassified to profit or loss	*(22)*	*(65)*	*110*
Translation differences (Note 6)	611	(798)	629
Total items that may be reclassified subsequently to profit or loss	*611*	*(798)*	*629*
Other comprehensive income for the period, net of tax	589	(863)	739
Total comprehensive income for the period	(3,691)	(3,627)	(19,076)
Attributable to			
Owners of Implantica AG	(3,747)	(3,824)	**(19,220)**
Non-controlling interests	56	197	**144**
Total comprehensive income for the period	(3,691)	(3,627)	(19,076)

Condensed consolidated statement of financial position

in thousands of EUR	31 Mar 2026	31 Mar 2025	31 Dec 2025
ASSETS			
Current assets			
Cash and cash equivalents (Note 7)	45,524	25,753	19,862
Accounts receivable	973	820	666
Other current receivables	1,920	1,753	1,980
Inventories	264	206	305
Current financial assets (Note 7)	-	34,530	29,000
Total current assets	48,681	63,062	51,813
Non-current assets			
Property, plant and equipment	198	237	217
Right-of-use assets	211	493	207
Intangible assets (Note 4)	32,451	34,975	32,768
Deferred tax assets	895	966	895
Total non-current assets	33,755	36,671	34,087
Total assets	82,436	99,733	85,900
LIABILITIES AND EQUITY			
Current liabilities			
Trade payables	27	40	34
Financial liabilities	101	302	87
Financial liabilities due to ultimate main shareholder	1	1	1
Other current liabilities	2,802	2,208	2,788
Total current liabilities	2,931	2,551	2,910
Non-current liabilities			
Financial liabilities	113	214	122
Pension liability	308	404	274
Total non-current liabilities	421	618	396
Total liabilities	3,352	3,169	3,306
Equity			
Share capital (Note 6)	129,624	129,351	129,596
Capital reserves	370,550	370,548	370,550
Treasury share reserve	-	(66)	-
Translation differences (Note 6)	15,012	13,128	14,474
Retained earnings	(433,724)	(414,016)	(429,592)
Total equity attributable to owners of Implantica AG	81,462	98,945	85,028
Non-controlling interests	(2,378)	(2,381)	(2,434)
Total equity	79,084	96,564	82,594
Total liabilities and equity	82,436	99,733	85,900

Condensed consolidated statement of cash flows

in thousands of EUR	Jan to Mar 2026	Jan to Mar 2025	Jan to Dec 2025
Loss for the period	(4,280)	(2,764)	(19,815)
Adjustments for			
Depreciation, amortisation and impairment	361	408	2,790
Financial income	(213)	(1,445)	(937)
Financial expenses	632	32	197
Income taxes	3	4	32
Share-based compensation	181	33	1,507
Other financial result	(6)	(7)	(23)
Change in pension liabilities	8	10	48
Other non-cash items	5	(20)	49
Changes in net working capital			
Decrease / (increase) accounts receivable	(307)	(231)	(77)
Decrease / (increase) other current receivables	(92)	170	(77)
Decrease / (increase) inventories	41	20	(79)
(Decrease) / increase trade payables	(7)	(257)	(263)
(Decrease) / increase other current liabilities	14	(478)	86
Net cash outflow from operating activities	(3,660)	(4,525)	(16,562)
Cash flows from investing activities			
Purchase of property, plant and equipment	-	(25)	(64)
Investment in intangible assets (Note 4)	-	(8)	(8)
Investment in fixed term deposits (Note 7)	-	(34,220)	(63,220)
Redemption of fixed term deposits (Note 7)	29,000	-	34,374
Interest received	302	10	676
Net cash inflow/(outflow) from investing activities	29,302	(34,243)	(28,242)
Cash flows from financing activities			
Treasury shares disposal	-	-	5
Payment of lease liabilities	(22)	(72)	(184)
Interest paid	(2)	(4)	(12)
Net cash outflow from financing activities	(24)	(76)	(191)
Net increase/(decrease) in cash and cash equivalents	25,618	(38,844)	(44,995)
Effect of exchange rate fluctuations on cash held	44	45	305
Cash and cash equivalents at beginning of period	19,862	64,552	64,552
Cash and cash equivalents at end of period	45,524	25,753	19,862

Condensed consolidated statement of changes in equity

	Jan to Mar 2026							
in thousands of EUR	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2025	129,596	370,550	-	14,474	(429,592)	85,028	(2,434)	82,594
Loss for the period	-	-	-	-	(4,263)	(4,263)	(17)	(4,280)
Other comprehensive income (net)	-	-	-	538	(22)	516	73	589
Total comprehensive income (net)	-	-	-	538	(4,285)	(3,747)	56	(3,691)
Share-based compensation	28	-	-	-	153	181	-	181
Total transactions with shareholders	28	-	-	-	153	181	-	181
Balance at 31 March 2026	129,624	370,550	-	15,012	(433,724)	81,462	(2,378)	79,084

	Jan to Mar 2025							
in thousands of EUR	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2024	129,351	370,548	(71)	14,178	(411,270)	102,736	(2,578)	100,158
Loss for the period	-	-	-	-	(2,709)	(2,709)	(55)	(2,764)
Other comprehensive income (net)	-	-	-	(1,050)	(65)	(1,115)	252	(863)
Total comprehensive income (net)	-	-	-	(1,050)	(2,774)	(3,824)	197	(3,627)
Share-based compensation	-	-	5	-	28	33	-	33
Total transactions with shareholders	-	-	5	-	28	33	-	33
Balance at 31 March 2025	129,351	370,548	(66)	13,128	(414,016)	98,945	(2,381)	96,564

Notes

NOTE 1 General information

Implantica AG (the 'Company') is domiciled at Austrasse 15, 9490 Vaduz, Liechtenstein. These condensed consolidated interim financial statements ('interim financial statements') as at and for the three months ended 31 March 2026 comprise the Company and its subsidiaries (together referred to as the 'Group'). The Group is primarily involved in the research and distribution of medical implants. Implantica AG was admitted to trading on the Nasdaq First North Premier Growth Market in Stockholm in September 2020. Implantica AG is ultimately controlled by the Implantica Founder, Dr. Peter Forsell.

These interim financial statements were authorized for issue by the Company's Board of Directors on 21 May 2026. As of this date, no material events after the reporting date have occurred.

NOTE 2 Summary of significant accounting policies

Basis of preparation

These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group's consolidated financial statements as at and for the year ended 31 December 2025 ('last financial statements'). These interim financial statements do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS Accounting Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last financial statements.

For the preparation of these financial statements the historical cost basis except for all those assets and liabilities measured at fair value has been applied. All amounts are presented in EUR, and are rounded to the nearest thousand of EUR with the consequence that the rounded amounts may not add to the rounded total in all cases. All ratios and variances are calculated using the underlying amounts rather than the rounded amounts.

Critical accounting estimates and judgements

In preparing these interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

NOTE 3 General accounting policies

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2025.

There were no new standards or amendments to existing standards that have a material effect on the Group's interim financial statements.

Accounting standards issued but not yet effective

A number of new accounting standards and amendments to accounting standards are effective for annual periods beginning after 1 January 2026 and earlier application is permitted. The Group has not early adopted any of the forthcoming new or amended accounting standards in preparing these condensed consolidated interim financial statements.

NOTE 4 Intangible assets

	Jan to Mar	
in thousands of EUR	2026	2025
Net carrying amount at 1 January	32,768	35,292
Additions Jan to Mar	-	-
Amortization Jan to Mar	(316)	(316)
Translation differences	(1)	(1)
Net carrying amount at 31 March	32,451	34,975

For the first quarter research and development costs in the amount of EUR 1,695 thousand were recognized in profit or loss since the conditions for capitalization as intangible assets for these costs are not met.

NOTE 5 Earnings per share

	Jan to Mar		Jan to Dec
in thousands of EUR	2026	2025	2025
Loss for the period attributable to owners of Implantica AG	(4,263)	(2,709)	(19,626)
Weighted average % of Class A share capital in total share capital	83.8%	83.8%	83.8%
Weighted average % of Class B share capital in total share capital	16.2%	16.2%	16.2%
Class A shares			
Loss for the period attributable to Class A shareholders	(3,574)	(2,270)	(16,448)
Weighted average number of outstanding Class A shares	58,334,213	58,179,203	58,226,758
Basic and diluted (loss) per share Class A (in EUR)	(0.06)	(0.04)	(0.28)
Class B shares			
Loss for the period attributable to Class B shareholders	(689)	(439)	(3,178)
Weighted average number of Class B shares	1,125,000,000	1,125,000,000	1,125,000,000
Basic and diluted (loss) per share Class B (in EUR)	(0.00)	(0.00)	(0.00)

Earnings per category of shares

Earnings per class of shares (Note 6) are calculated on the basis of the net loss attributable to the shareholders of Implantica AG based on their portion of the share capital and the average number of outstanding shares (i.e. excluding treasury shares).

Anti-dilutive effect of potential outstanding shares

The impact of share-based compensation arrangements was not considered in the diluted earnings per share calculation for Class A shares for the periods presented because due to the net loss for these periods their effect would have been anti-dilutive.

NOTE 6 Equity

Share capital

The fully paid in share capital of the Group amounts to CHF 139,178 thousand (EUR 129,624 thousand) and is divided into 58,339,233 registered shares with a nominal value of CHF 2.00 each (Class A) and 1,125,000,000 with a nominal value of CHF 0.02 each (Class B). During the first quarter 2026 the Group issued a total number of 12,765 new Class A shares to settle existing equity-based compensation plans through using authorized capital.

Translation differences

During the first quarter 2026 the EUR/CHF exchange rate increased from 1.074 to 1.088. As a result, the group recognized a total profit of EUR 611 thousand in other comprehensive income related to the translation of financial statements of foreign operations and net investments in foreign operations.

NOTE 7 Cash and cash equivalents and financial assets

Following the redemption in January 2026 of the EUR 29,000 thousand term deposit held at 31 December 2025 as a current financial asset, the Group entered into a new term deposit agreement with the same Swiss bank for EUR 29,000 thousand, maturing on 30 April 2026, at an interest rate of 2.20%. As the term of this new deposit does not exceed three months, it is classified as cash and cash equivalents, whereas the previous deposit was classified as a current financial asset.

Other

Telephone conference

Implantica will hold a teleconference on 22 May 2026 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast

If you wish to participate via webcast, please use the following link:

https://implantica.events.inderes.com/q1-report-2026

Dial-in

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

https://events.inderes.com/implantica/q1-report-2026/dial-in

Financial calendar

10 June 2026	Annual General Meeting
21 August 2026	Interim Report Q2 2026
19 November 2026	Interim Report Q3 2026

Listing

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company is traded under the ticker symbol IMP A SDB and ISIN code SE0014855029.

Disclaimer statement

Some statements herein are forward-looking, and the actual outcome could be materially different. In addition to the factors explicitly commented upon, the actual outcome could be materially affected by other factors, for example: the impact of undesired side effects related to existing or future products, failures in handling of the quality system, obstacles in obtaining CE and FDA approvals and re-certifications, products may fail to become subject to insurance and reimbursement policies and risk not gaining widespread acceptance, clinical trials may prove to be unsuccessful and the impact of competing products.

Contacts

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone: +41 (0)79 335 09 49
E-mail: nicole.pehrsson@implantica.com

Peter Forsell, CEO
E-mail: peter.forsell@implantica.com

Andreas Öhrnberg, CFO
E-mail: andreas.oehrnberg@implantica.com

Implantica AG
Austrasse 15
9490 Vaduz
Liechtenstein

www.implantica.com